Bought
Maintained
Sold
Other funds holding ACLS
VPM
RP
VCM
Aviva's ACLS Position: Q1 2026 in Review
Aviva reduced its Axcelis (ACLS) stake by 10% in Q1 2026, selling an estimated $53.8K and leaving 5,308 shares worth $494K. The position accounts for ﹤0.01% of the portfolio, ranked #692.
Aviva first reported a position in ACLS in Q4 2021 and has held it in 15 quarters since. The position peaked at $2.05M in Q4 2021. 377 funds tracked by Wall St. Rank hold ACLS as of Q1 2026.
- Aviva held 5,308 shares of Axcelis worth $494K as of Q1 2026.
- Aviva sold 608 Axcelis shares in Q1 2026, an estimated $53.8K.
- Axcelis made up ﹤0.01% of Aviva's portfolio in Q1 2026, its #692 holding.
- Aviva first reported a position in Axcelis in Q4 2021 and has held it in 15 quarters since.
- Aviva's Axcelis position peaked at $2.05M in Q4 2021.
- 377 funds tracked by Wall St. Rank held Axcelis as of Q1 2026.
Based on Aviva's 13F filing for Q1 2026, filed 14 May 2026.